{
    "clinical_study": {
        "@rank": "122790", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 (adalimumab 40 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52."
            }, 
            {
                "arm_group_label": "Group 2 (sirukumab 100 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind)."
            }, 
            {
                "arm_group_label": "Group 3 (sirukumab 50 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind)."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to investigate the efficacy of sirukumab monotherapy compared with\n      adalimumab monotherapy in biologic na\u00efve subjects with active rheumatoid arthritis who are\n      intolerant to methotrexate, who are considered inappropriate for continued treatment with\n      methotrexate or who are inadequate responders to methotrexate."
        }, 
        "brief_title": "A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA\u00ae) Monotherapy in the Treatment of Active Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Arthritis, Rheumatoid", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, parallel-group, global, multicenter study of\n      subcutaneous (SC) sirukumab monotherapy compared with adalimumab monotherapy in subjects\n      with active rheumatoid arthritis. Approximately 510 subjects will be randomly assigned in a\n      1:1:1 ratio to receive treatment with adalimumab 40 mg SC every 2 weeks, sirukumab 100 mg SC\n      every 2 weeks, or 50 mg SC every 4 weeks, with approximately 170 subjects per treatment\n      group.  At Week 16, subjects in all treatment groups who have < 20% improvement from\n      baseline in both swollen and tender joint counts will qualify for early escape. The expected\n      duration of the study is 68 weeks.  This includes 52 weeks of treatment with study agent and\n      16 weeks of safety follow-up after the last study agent administration.  The study will end\n      when the last subject completes the last scheduled visit (Week 68 visit or completes the 16\n      week safety follow-up, whichever is later). Subject safety will be monitored through the end\n      of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening\n\n          -  Have moderately to severely active RA with at least 8 of 68 tender joints and 6 of 66\n             swollen joints, at screening and at baseline\n\n          -  Have previous or current treatment with methotrexate (MTX) and are considered\n             intolerant to MTX, and/or are considered inappropriate for treatment with MTX, and/or\n             an inadequate responder to methotrexate\n\n          -  Must not have received MTX or any other non-biologic DMARD including but not limited\n             to sulfasalazine, hydroxychloroquine, chloroquine, and bucillamine for at least 2\n             weeks prior to the first administration of the study agent\n\n          -  C-reactive protein >= 10.00 mg/L or erythrocyte sedimentation rate >=28 mm/hr at\n             screening\n\n        Exclusion Criteria:\n\n          -  Has Functional Class IV as defined by the ACR Classification of Functional Status in\n             Rheumatoid Arthritis\n\n          -  Has ever received biologic therapy for RA, including but not limited to the\n             following: TNF-alpha inhibitors, tocilizumab, rituximab, anakinra, abatacept\n\n          -  Has ever used tofacitinib therapy or any other JAK inhibitor\n\n          -  Has received intra-articular, intramuscular, or IV corticosteroids for RA, including\n             adrenocorticotrophic hormone during the 4 weeks prior to first study agent\n             administration\n\n          -  Has received leflunomide within 24 months before the first study agent administration\n             and has not undergone a drug elimination procedure, unless the M1 metabolite is\n             measured and is undetectable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "510", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019472", 
            "org_study_id": "CR103111", 
            "secondary_id": "CNTO136ARA3005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1 (adalimumab 40 mg)", 
                "description": "SC injections", 
                "intervention_name": "adalimumab 40 mg", 
                "intervention_type": "Biological", 
                "other_name": "HUMIRA\u00ae"
            }, 
            {
                "arm_group_label": "Group 2 (sirukumab 100 mg)", 
                "description": "SC injections", 
                "intervention_name": "sirukumab 100 mg", 
                "intervention_type": "Biological", 
                "other_name": "CNTO 136"
            }, 
            {
                "arm_group_label": "Group 3 (sirukumab 50 mg)", 
                "description": "SC injections", 
                "intervention_name": "sirukumab 50 mg", 
                "intervention_type": "Biological", 
                "other_name": "CNTO 136"
            }, 
            {
                "arm_group_label": [
                    "Group 2 (sirukumab 100 mg)", 
                    "Group 3 (sirukumab 50 mg)"
                ], 
                "description": "SC injections", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rheumatoid arthritis", 
            "CNTO 136", 
            "Sirukumab", 
            "Adalimumab", 
            "HUMIRA\u00ae"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR103111"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elizabethtown", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salisbury", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middleburg Heights", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wyomissing", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chesapeake", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olsztyn", 
                        "country": "Poland"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kragujevac", 
                        "country": "Serbia"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odessa", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sympheropol", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Withdrawn"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Poland", 
                "Serbia", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA\u00ae Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Argentina: Human Research Bioethics Committee", 
                "Brazil: National Committee of Ethics in Research", 
                "Brazil: National Health Surveillance Agency", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Bulgaria: Ethics committee", 
                "Chile: Instituto de Salud P\u00fablica de Chile", 
                "Chile: Comit\u00e9 de \u00c9tica Cient\u00edfico", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Colombia: Institutional Review Board", 
                "Czech Republic: Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Ethics Commission", 
                "Germany: Paul-Ehrlich-Institut", 
                "Hungary: Institutional Ethics Committee", 
                "Hungary: National Institute of Pharmacy", 
                "Lithuania: Bioethics Committee", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Mexico: Ethics Committee", 
                "Mexico: Federal Commission for Sanitary Risks Protection", 
                "Peru: Ethics Committee", 
                "Peru: Instituto Nacional de Salud", 
                "Poland: Ethics Committee", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Republic of Moldova: Ministry of Health", 
                "Romania: Ethics Committee", 
                "Romania: National Medicines Agency", 
                "Russia: Ethics Committee", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Serbia: Ethics Committee", 
                "Serbia: Agency for Drugs and Medicinal Devices", 
                "South Africa: Human Research Ethics Committee", 
                "South Africa: Medicines Control Council", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
                "Sweden: Medical Products Agency", 
                "Ukraine: State Pharmacological Center - Ministry of Health", 
                "Ukraine: Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in Disease Activity Index Score 28 using erythrocyte sedimentation rate [DAS28 (ESR)]", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Percentage of subjects with an American College of Rheumatology 50 (ACR 50) response", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of subjects with DAS28 (ESR) remission", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Percentage of subjects with an ACR 20 response", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}